Eagle Pharmaceuticals, Inc. (EGRX)

NASDAQ: EGRX · IEX Real-Time Price · USD
4.550
-0.060 (-1.30%)
At close: Apr 22, 2024, 4:00 PM
4.560
+0.010 (0.22%)
After-hours: Apr 22, 2024, 4:51 PM EDT
-1.30%
Market Cap 59.09M
Revenue (ttm) 257.55M
Net Income (ttm) 11.95M
Shares Out 12.99M
EPS (ttm) 0.91
PE Ratio 5.00
Forward PE 1.14
Dividend n/a
Ex-Dividend Date n/a
Volume 232,530
Open 4.600
Previous Close 4.610
Day's Range 4.510 - 4.810
52-Week Range 4.100 - 30.400
Beta 0.41
Analysts Sell
Price Target 17.00 (+273.63%)
Earnings Date May 7, 2024

About EGRX

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-... [Read more]

Sector Healthcare
IPO Date Feb 12, 2014
Employees 134
Stock Exchange NASDAQ
Ticker Symbol EGRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for EGRX stock is "Sell" and the 12-month stock price forecast is $17.0.

Price Target
$17.0
(273.63% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida

-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versu...

7 days ago - GlobeNewsWire

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the L...

10 days ago - GlobeNewsWire

Shareholders of Eagle Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before February 9, 2024 to Discuss Your Rights - EGRX

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Fa...

2 months ago - PRNewsWire

Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024 - EGRX

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 9, 2024 in Eagle Pharmaceuticals, Inc. Lawsuit - EGRX

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX

NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period...

2 months ago - PRNewsWire

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...

2 months ago - Accesswire

Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) - February 9, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

LOS ANGELES , Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit again...

2 months ago - PRNewsWire

Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of invest...

2 months ago - Business Wire

Shareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRX

NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / February 8, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securi...

2 months ago - Accesswire

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsui...

2 months ago - PRNewsWire

FINAL DEADLINE FRIDAY: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...

2 months ago - Accesswire

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Feb. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities l...

2 months ago - PRNewsWire

FEBRUARY 9 DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...

2 months ago - Accesswire

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

NEW YORK , Feb. 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 an...

2 months ago - PRNewsWire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...

2 months ago - Accesswire

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...

2 months ago - Accesswire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)

NEW YORK , Feb. 2, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period...

2 months ago - PRNewsWire

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Eagle Pharmaceuticals, Inc. ("...

2 months ago - Accesswire